Response to Immune Checkpoint Inhibition as Monotherapy or in Combination With Chemotherapy in Metastatic ROS1-Rearranged Lung Cancers is a research paper published in JTO Clinical and Research Reports (2021). On theSindex it has a DataRank of 0.529. It has been cited 33 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.529
From this paper's citation signal
Citation Network Contribution
0
Citation network not refreshed for this result
This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.
Learn more about DataRank methodology →National Cancer Institute
Grant: P30 CA00874
National Cancer Institute
Grant: T32CA071345
NCI NIH HHS
Grant: P30 CA008748
National Institutes of Health
Grant: 5T32CA071345-08
Training Program in Cancer Biology
GlaxoSmithKline
National Institutes of Health
Exelixis
Relay Therapeutics
Genentech
Helsinn Therapeutics
Mylan
Northwell Health
Novartis
Takeda Pharmaceutical Company
Puma Biotechnology
AstraZeneca
BeiGene
Eli Lilly and Company
Heron Therapeutics
Merck
Roche
Bayer
FWCI
2.20
Citation Percentile
0.9%
Citation Trend
Fields of Study
Keywords
Sustainable Development Goals